Research graph
References from Differentiation–Proliferation Imbalance and Therapy- Associated State Remodeling in MYCN-Non-Amplified Neuroblastoma: Multi-Cohort and Paired Single-Cell Analyses. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/nrdp.2016.78
10.1038/nrdp.2016.78 · 2016 · External reference
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
10.1200/jco.2014.59.4648 · 2015 · External reference
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
10.1200/jco.21.00278 · 2021 · External reference
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
10.1126/science.6719137 · 1984 · External reference
The genetic landscape of high-risk neuroblastoma
10.1038/ng.2529 · 2013 · External reference
A mechanistic classification of clinical phenotypes in neuroblastoma
10.1126/science.aat6768 · 2018 · External reference
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction
10.1186/s13059-015-0694-1 · 2015 · External reference
Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma
10.1200/po.19.00072 · 2019 · External reference
Neuroblastoma is composed of two super-enhancer-associated differentiation states
10.1038/ng.3899 · 2017 · External reference
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries
10.1038/ng.3921 · 2017 · External reference
Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma
10.1038/s41467-023-38239-5 · 2023 · External reference
Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma
10.1038/s41588-021-00806-1 · 2021 · External reference
Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin
10.1038/s41588-021-00818-x · 2021 · External reference
Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring
10.1038/s41588-025-02158-6 · 2025 · External reference
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
10.1186/gb-2008-9-10-r150 · 2008 · External reference
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
10.18632/oncotarget.27329 · 2020 · External reference
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
10.1126/sciadv.abn1382 · 2022 · External reference
limma powers differential expression analyses for RNA-sequencing and microarray studies
10.1093/nar/gkv007 · 2015 · External reference
10.1073/pnas.0506580102
10.1073/pnas.0506580102 · 2005 · External reference
The Molecular Signatures Database (MSigDB) hallmark gene set collection
10.1016/j.cels.2015.12.004 · 2015 · External reference
Unresolved reference
2013 · External reference
decoupleR: ensemble of computational methods to infer biological activities from omics data
10.1093/bioadv/vbac016 · 2022 · External reference
Benchmark and integration of resources for the estimation of human transcription factor activities
10.1101/gr.240663.118 · 2019 · External reference
Perturbation-response genes reveal signaling footprints in cancer gene expression
10.1038/s41467-017-02391-6 · 2018 · External reference
Integrated intra- and intercellular signaling knowledge for multicellular omics analysis
10.15252/msb.20209923 · 2021 · External reference
Defining a Cancer Dependency Map
10.1016/j.cell.2017.06.010 · 2017 · External reference
Cell state plasticity in neuroblastoma
10.1016/j.ejcped.2024.100184 · 2024 · External reference
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification
10.1038/s41416-024-02666-y · 2024 · External reference
Impact of Genomic and Clinical Factors on Outcome of Children ≥ 18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. Clin
10.1158/1078-0432.ccr-22-3032 · 2023 · External reference
Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects
10.3390/cancers16030544 · 2024 · External reference
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes
10.1200/edbk_349783 · 2022 · External reference
10.1016/j.isci.2024.111433
10.1016/j.isci.2024.111433 · 2024 · External reference
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells
10.1158/2159-8290.cd-24-0046 · 2024 · External reference
An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs
10.1186/s13059-024-03309-4 · 2024 · External reference
